Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycology

Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis

Takahiro Takazono, Yuya Ito, Masato Tashiro, Keitaro Nishimura, Tomomi Saijo, Kazuko Yamamoto, Yoshifumi Imamura, Taiga Miyazaki, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa
David W. Warnock, Editor
Takahiro Takazono
aDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Takahiro Takazono
Yuya Ito
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Tashiro
aDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keitaro Nishimura
aDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomomi Saijo
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuko Yamamoto
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshifumi Imamura
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taiga Miyazaki
aDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsunori Yanagihara
cDepartment of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Mukae
bDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Izumikawa
aDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Warnock
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00095-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The Aspergillus-specific lateral-flow device (AspLFD) test is a newly developed point-of-care diagnostic method for invasive pulmonary aspergillosis. However, evidence of the diagnostic performance of the AspLFD for chronic pulmonary aspergillosis (CPA) is limited. Therefore, we conducted a retrospective study to investigate this in comparison with the galactomannan (GM) β-d-glucan (BDG) test. Fifty patients with chronic pulmonary aspergillosis and 65 patients with respiratory disease, as a control, were enrolled in this study. The majority of the CPA disease entities were chronic pulmonary aspergillosis (64.0%, n = 32), followed by subacute invasive pulmonary aspergillosis (IPA) (20.0%, n = 10) and simple pulmonary aspergilloma (SPA) (16.0%, n = 8). The sensitivity and specificity of the AspLFD test in serum samples were 62.0% and 67.7%, respectively. The GM test (cutoff index, 1.54) showed a sensitivity of 22% and a specificity of 92.3%, while the sensitivity and specificity of the BDG test (cutoff, 19.3 pg/ml) were 48% and 90.8%, respectively. In bronchoalveolar lavage fluid samples, the AspLFD test showed a sensitivity of 66.7% and a specificity of 69.2%, while those of the GM test (cutoff index, 0.6) were 72.7% and 83.1%, respectively. The Aspergillus precipitating antibody test had 70% sensitivity. Unlike the Aspergillus precipitating antibody test, the AspLFD on serum samples showed similar sensitivity to non-fumigatus Aspergillus species. Patients with false-positive results for the AspLFD on serum samples were of a significantly higher age and had a higher prevalence of cavitary lesions in chest computed tomography than patients with negative results in the control group. Given the results in this study, the performance of the AspLFD using serum was acceptable as a point-of-care test for the diagnosis of CPA.

INTRODUCTION

Chronic pulmonary aspergillosis (CPA) is a slowly progressive disease that presents a variety of clinical courses and radiological findings. The definitive diagnosis of CPA is not easy because of the low sensitivity of mycological culture (1–4) and the difficulty of performing histopathological examination due to patients’ severe general condition. Therefore, serodiagnosis is indispensable for the diagnosis of CPA. However, the galactomannan (GM) assay does not possess high sensitivity or specificity for the diagnosis of CPA (1, 3), unlike the Aspergillus IgG precipitating antibody test (1). Aspergillus IgG antibody enzyme-linked immunosorbent assays (ELISAs) are available in several countries, and some of them are reported to show a high sensitivity and specificity for the diagnosis of CPA, though evidence for diagnosing CPA caused by non-fumigatus Aspergillus strains is lacking (5–7).

The number of CPA patients is estimated to be up to 3,000,000 per year worldwide (8); however, some CPA cases are considered to be undiagnosed in resource-limited countries, and therefore, point-of-care (POC) diagnostic methods are required (9). The diagnostic tests described above need at least half a day of turnaround time. The Aspergillus-specific lateral-flow device (AspLFD) is a newly developed POC diagnostic method for IPA. It uses the mouse monoclonal antibody JF5, which binds to a protein epitope present on an extracellular glycoprotein antigen secreted constitutively during the active growth of Aspergillus fumigatus. This test can detect Aspergillus antigens in human serum within 15 min (10). An early clinical trial showed that the AspLFD test is comparable to the GM test in serum in terms of diagnosing IPA, with sensitivity and specificity of 81.8% and 98%, respectively (11). However, evidence of the diagnostic performance of the AspLFD for CPA is limited. Therefore, we conducted a retrospective study to investigate the diagnostic performance of the AspLFD in serum and bronchoalveolar lavage (BAL) fluid in comparison with the GM assay in serum/BAL fluid and the β-d-glucan (BDG) assay in serum.

MATERIALS AND METHODS

Patients.CPA patients who were diagnosed between 2008 and 2017 and had available stored serum or bronchoalveolar lavage (BAL) fluid samples taken before antifungal treatments were enrolled in this study. Patients with respiratory diseases and without Aspergillus infection who underwent all the following tests for the diagnosis of respiratory infectious diseases in the same period were enrolled as control group patients: the required tests were bronchoscopy and serum/BAL fluid GM, BDG, and Aspergillus precipitating antibody assays. BAL was performed, using 20 to 40 ml of normal saline, at the site of the pulmonary lesion. Clinical information, including sex, age, underlying diseases, medication, laboratory test results, culture results, and chest computed tomography (CT) findings, was retrospectively collected from medical records. This study was approved by the Nagasaki University School of Medicine Research Ethics Committee (approval number 15032356-2).

Case definition.Criteria for CPA were based on the diagnostic criteria of the European Society for Clinical Microbiology and Infectious Diseases/European Respiratory Society guidelines, including (i) one or more cavities with or without a fungal ball present or nodules identified on computed tomography scan and (ii) direct evidence of Aspergillus infection or positive result of Aspergillus precipitating antibody assay (12). Patients with CPA were further classified into simple pulmonary aspergillosis (13), chronic cavitary aspergillosis (CCPA), and subacute invasive aspergillosis (SAIA) groups according to the guidelines (12).

AspLFD.The newly improved, CE-marked Aspergillus lateral flow device (AspLFD; OLM Diagnostics, Newcastle upon Tyne, United Kingdom) was used in accordance with the manufacturer’s protocol. Serum and BAL fluid samples stored at −80°C were thawed, vortexed, and centrifuged for 1 min at 14,000 × g. Serum samples were mixed with sample buffer (provided by OLM) at a ratio of 1:2 and heated in the heat block at 100°C for 3 min. Amounts of 70 μl of treated serum and untreated BAL fluid samples were applied to the port of the cassette, and the results read 15 min later. To eliminate bias, two interpreters read the AspLFD test results without knowing the diagnosis. If the two readings did not match, a third interpreter blinded to clinical information determined the results.

Galactomannan assay, β-d-glucan assay, and Aspergillus precipitating antibody.The Platelia Aspergillus enzyme immunoassay (EIA) (Bio-Rad, Tokyo, Japan) was used for the GM assay in serum and BAL fluid samples. The FSK1 Aspergillus immunodiffusion system (Microgen Bioproducts Ltd., United Kingdom) was used for Aspergillus precipitating antibody assays in serum samples according to the manufacturer’s instructions. The Fungitec G test MK-II (Nissui, Tokyo, Japan) was used for BDG assays in plasma samples according to the manufacturer’s instructions; briefly, amounts of 5 μl of plasma samples were mixed with the pretreatment solution and heated at 37°C for 10 min in a 96-well plate. After a heating step, amounts of 100 μl of reactive solutions were added to the samples and the mixtures stirred for 60 s and then heated again at 37°C for 30 min. The absorbance was measured at 405/492 nm. All the tests were performed by technicians who were blinded to the patients’ detailed conditions.

Statistical analysis.The differences in categorical variables or continuous numbers were analyzed by Fisher’s exact test or unpaired t test. A P value of <0.05 was considered statistically significant. Receiver operating characteristic (ROC) curve analyses were performed on data from GM and BDG assays, and areas under the curves (AUCs), including 95% confidence intervals, were evaluated to assess the diagnostic ability to distinguish between CPA patients and control group patients with respiratory diseases. The Youden index was applied to determine the optimized cutoff in ROC curve analysis.

RESULTS

Patients’ characteristics.A total of 50 CPA patients and 65 disease control patients were enrolled, and the clinical characteristics of these patients are summarized in Table 1. The majority of CPA disease entities were CCPA (64%, n = 32), followed by SAIA (20%, n = 10) and SPA (16%, n = 8). Bronchoscopy was performed in 41 of 50 CPA patients, and BAL stock samples were available in 34 cases. The underlying pulmonary diseases were interstitial pneumonia, nontuberculosis mycobacterium infection, prior pulmonary tuberculosis infection, chronic obstructive pulmonary diseases, and diabetes mellitus. Steroid or immunosuppressant use was observed as a systemic immunosuppressive factor, but no patient had neutropenia. A. fumigatus (56%) was the main pathogen isolated in sputum or BAL samples; 13 cases (26%) were culture negative.

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics of patients enrolled in this study and results for each test

AspLFD.The sensitivity and specificity of the Aspergillus-specific lateral-flow device (AspLFD) were 62% and 67.7%, respectively, in serum samples and 66.7% and 69.2%, respectively, in BAL fluid samples (Table 2). In serum samples, the concordance rates of the LFD test with the GM test (cutoff index, 1.54) and the BDG test (cutoff, 19.3 pg/ml) were 65.2 and 60.0%, respectively. In BAL fluid samples, the concordance rate of the LFD test with the GM test (cutoff index, 0.6) was 64.3%. Cause analysis of AspLFD false-positive cases in the control group was performed; the patients with AspLFD false-positive results were significantly older and had higher prevalences of a cavitary lesion(s) in the chest CT than the patients with negative results in the control group (Table 3). In addition, these patients showed significantly higher GM indices than patients with negative AspLFD results. The diagnostic performances for the use of AspLFD in combination with GM or BDG tests are summarized in Table 2.

View this table:
  • View inline
  • View popup
TABLE 2

Diagnostic performances of the AspLFD, GM, and BDG tests

View this table:
  • View inline
  • View popup
TABLE 3

Cause analysis of false-positive serum AspLFD results in control group

GM antigen, β-d-glucan, and Aspergillus precipitating antibody assays.The sensitivity and specificity of the serum GM antigen assay were 64% and 43.1%, respectively, at a cutoff of 0.5 and 34% and 72.3% at a cutoff of 1.0. The optimized cutoff index of this assay from the ROC curve was 1.54, with a sensitivity of 22% and a specificity of 92.3%, while the BAL fluid GM antigen assay showed higher sensitivity and specificity of 72.7% and 83.1%, respectively, at a cutoff index of 0.6 optimized from the ROC curve (Table 2). The AUCs of the ROC curves were 0.561 and 0.824, respectively (Fig. 1A and B). The serum BDG assay showed low sensitivity (40.6%) and high specificity (90.7%) at the 20-pg/ml cutoff value, which is the optimized cutoff value for Candidiasis. The optimized CPA cutoff value here was 19.3 pg/ml, with 48% sensitivity and 90.8% specificity. Its AUC for the ROC curve was 0.721, which was superior to that of the serum GM assay. The Aspergillus precipitating antibody assay showed a sensitivity of 70%.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Receiver operating characteristic curves of galactomannan (GM) antigen tests in serum and bronchoalveolar lavage (BAL) fluid and β-d-glucan test in serum. Areas under the curves (95% confidence interval) for serum GM (A), bronchoalveolar GM (B), and serum β-d-glucan test (C) were 0.561 (0.4545 to 0.6679), 0.824 (0.7322 to 0.9163), and 0.721 (0.6259 to 0.8156), respectively.

Positivity rates for non-fumigatus Aspergillus spp.The positivity rates of each test in nine CPA patients with disease caused by non-fumigatus Aspergillus spp. are summarized in Table 4. The sensitivity of the LFD for serum samples was 66.7%, similar to the result for A. fumigatus (62.9%). The BDG assay (cutoff, 19.3 pg/ml) showed results similar to those of the LFD. However, the GM assay (cutoff index, 1.54) and the Aspergillus precipitating antibody assay both showed a low sensitivity of 22.2% in this population.

View this table:
  • View inline
  • View popup
TABLE 4

Positivity rate of each test in patients with CPA caused by non-fumigatus Aspergillus spp.

DISCUSSION

In this study, the serum AspLFD assay showed better performance than the serum GM or BDG assay for the diagnosis of CPA. Moreover, its sensitivity was not inferior to that of the Aspergillus precipitating antibody assay, and unlike the Aspergillus precipitating antibody assay, it did not show any species specificity. The AspLFD also showed a high false-positive rate of 32% in the respiratory disease control group; however, since two factors, higher age and cavitary lesions, observed as false-positive factors in the cause analysis are also the common risk factors of CPA (12, 14), these cases could be undiagnosed CPA cases. The sensitivity and specificity of the AspLFD for serum samples were similar to those from a recent study in nonneutropenic invasive pulmonary aspergillosis (IPA) patients (15).

On the other hand, the diagnostic performance of the AspLFD in BAL fluid samples was similar to its performance in serum samples and, moreover, slightly inferior to that of the GM assay in BAL fluid samples. In addition, given its nature as a POC test, the utility of the AspLFD for BAL fluid samples might be limited. A recent study assessed the performance of the AspLFD in BAL fluid samples and reported that the LFD was positive in only 7% of CPA patients (16), which was an extremely low sensitivity compared to recent studies for the diagnosis of IPA (15, 17). However, the sensitivity of the BAL fluid GM index was also lower (41% at a cutoff value of 0.5) in that study (16) than in our study or other previous studies (18–20). The proportion of each disease entity of CPA in that study did not differ from those in our study. However, the volume of lavage fluid used for BAL was not described in the study; it is possible that a difference in lavage fluid volume affected the result of each test. Standardization of the method for bronchial washing is desirable; however, it might be difficult, as the amount of fluid recovered varies depending on the location of the focus of infection in the lungs. Due to the nature of the lateral-flow device’s qualitative test, there could be a difference in interpreting the positive line.

This study has several limitations, including the small size of the patient cohort and the fact that it is a single-center retrospective study. Another limitation is that Aspergillus IgG antibody ELISAs were not used for comparison, as these are not commercially available in Japan. The essential limitation in this research area is the difficulty of CPA diagnosis, as gold standards of diagnosis, such as histopathological findings and fungal culture tests, are difficult to satisfy; additionally, the utility of the Aspergillus antibody test for non-fumigatus Aspergillus spp. might be limited.

In conclusion, to the best of our knowledge, this is the first study to evaluate the performance of the AspLFD in serum for the diagnosis of CPA. Given the results reported here, the performance of AspLFD was not sufficiently good but was tolerable for the diagnosis of CPA; moreover, the best advantage of this test over other serodiagnostic tests is its short turnaround time, the most important requirement for point-of-care test. The AspLFD has potential as a screening test for CPA in clinics or resource-limited countries, but further prospective studies with large numbers of patients are required.

ACKNOWLEDGMENTS

Newly improved LFD tests used in this study were purchased from OLM Diagnostics in 2018. OLM Diagnostics was not involved in planning the study design, in data collection, analysis, or interpretation, or in the writing of the manuscript.

T. Takazono and K. Izumikawa planned the research design and drafted the manuscript. Y. Ito and K. Nishimura tested the patients’ samples. M. Tashiro, T. Saijo, K. Yamamoto, Y. Imamura, and T. Miyazaki collected patient’s clinical data. K. Yanagihara and H. Mukae revised the manuscript. All authors read and approved the submitted version.

The authors declare no conflicts of interest associated with the manuscript.

FOOTNOTES

    • Received 19 January 2019.
    • Returned for modification 11 February 2019.
    • Accepted 27 February 2019.
    • Accepted manuscript posted online 6 March 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Kitasato Y,
    2. Tao Y,
    3. Hoshino T,
    4. Tachibana K,
    5. Inoshima N,
    6. Yoshida M,
    7. Takata S,
    8. Okabayashi K,
    9. Kawasaki M,
    10. Iwanaga T,
    11. Aizawa H
    . 2009. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 14:701–708. doi:10.1111/j.1440-1843.2009.01548.x.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Kohno S,
    2. Izumikawa K,
    3. Ogawa K,
    4. Kurashima A,
    5. Okimoto N,
    6. Amitani R,
    7. Kakeya H,
    8. Niki Y,
    9. Miyazaki Y
    , Japan Chronic Pulmonary Aspergillosis Study Goup (JCPASG). 2010. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61:410–418. doi:10.1016/j.jinf.2010.08.005.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Nam HS,
    2. Jeon K,
    3. Um SW,
    4. Suh GY,
    5. Chung MP,
    6. Kim H,
    7. Kwon OJ,
    8. Koh WJ
    . 2010. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 14:e479–e482. doi:10.1016/j.ijid.2009.07.011.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Shin B,
    2. Koh WJ,
    3. Jeong BH,
    4. Yoo H,
    5. Park HY,
    6. Suh GY,
    7. Kwon OJ,
    8. Jeon K
    . 2014. Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. J Infect 68:494–499. doi:10.1016/j.jinf.2014.01.005.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Baxter CG,
    2. Denning DW,
    3. Jones AM,
    4. Todd A,
    5. Moore CB,
    6. Richardson MD
    . 2013. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect 19:E197–E204. doi:10.1111/1469-0691.12133.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Fujiuchi S,
    2. Fujita Y,
    3. Suzuki H,
    4. Doushita K,
    5. Kuroda H,
    6. Takahashi M,
    7. Yamazaki Y,
    8. Tsuji T,
    9. Fujikane T,
    10. Osanai S,
    11. Sasaki T,
    12. Ohsaki Y
    . 2016. Evaluation of a quantitative serological assay for diagnosing chronic pulmonary aspergillosis. J Clin Microbiol 54:1496–1499. doi:10.1128/JCM.01475-15.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Page ID,
    2. Baxter C,
    3. Hennequin C,
    4. Richardson MD,
    5. van Hoeyveld E,
    6. van Toorenenbergen AW,
    7. Denning DW
    . 2018. Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. Diagn Microbiol Infect Dis 91:47–51. doi:10.1016/j.diagmicrobio.2018.01.001.
    OpenUrlCrossRef
  8. 8.↵
    1. Bongomin F,
    2. Gago S,
    3. Oladele RO,
    4. Denning DW
    . 2017. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 3:E57. doi:10.3390/jof3040057.
    OpenUrlCrossRef
  9. 9.↵
    1. Denning DW,
    2. Page ID,
    3. Chakaya J,
    4. Jabeen K,
    5. Jude CM,
    6. Cornet M,
    7. Alastruey-Izquierdo A,
    8. Bongomin F,
    9. Bowyer P,
    10. Chakrabarti A,
    11. Gago S,
    12. Guto J,
    13. Hochhegger B,
    14. Hoenigl M,
    15. Irfan M,
    16. Irurhe N,
    17. Izumikawa K,
    18. Kirenga B,
    19. Manduku V,
    20. Moazam S,
    21. Oladele RO,
    22. Richardson MD,
    23. Tudela JLR,
    24. Rozaliyani A,
    25. Salzer HJF,
    26. Sawyer R,
    27. Simukulwa NF,
    28. Skrahina A,
    29. Sriruttan C,
    30. Setianingrum F,
    31. Wilopo BAP,
    32. Cole DC,
    33. Getahun H
    . 2018. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg Infect Dis 24:1312. doi:10.3201/eid2408.17-1312.
    OpenUrlCrossRef
  10. 10.↵
    1. Thornton CR
    . 2008. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 15:1095–1105. doi:10.1128/CVI.00068-08.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. White PL,
    2. Parr C,
    3. Thornton C,
    4. Barnes RA
    . 2013. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 51:1510–1516. doi:10.1128/JCM.03189-12.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Denning DW,
    2. Cadranel J,
    3. Beigelman-Aubry C,
    4. Ader F,
    5. Chakrabarti A,
    6. Blot S,
    7. Ullmann AJ,
    8. Dimopoulos G,
    9. Lange C
    , on behalf of the European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. 2016. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47:45–68. doi:10.1183/13993003.00583-2015.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Chong GM,
    2. van der Beek MT,
    3. von Dem Borne PA,
    4. Boelens J,
    5. Steel E,
    6. Kampinga GA,
    7. Span LF,
    8. Lagrou K,
    9. Maertens JA,
    10. Dingemans GJ,
    11. Gaajetaan GR,
    12. van Tegelen DW,
    13. Cornelissen JJ,
    14. Vonk AG,
    15. Rijnders BJ
    . 2016. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis. J Antimicrob Chemother 71:3528–3535. doi:10.1093/jac/dkw323.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Smith NL,
    2. Denning DW
    . 2011. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37:865–872. doi:10.1183/09031936.00054810.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Jenks JD,
    2. Mehta SR,
    3. Taplitz R,
    4. Aslam S,
    5. Reed SL,
    6. Hoenigl M
    . 2018. Point-of care diagnosis of invasive aspergillosis in in non-neutropenic patients: Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test in bronchoalveolar lavage. Mycoses 62:230–236. doi:10.1111/myc.12881.
    OpenUrlCrossRef
  16. 16.↵
    1. Salzer HJF,
    2. Prattes J,
    3. Flick H,
    4. Reimann M,
    5. Heyckendorf J,
    6. Kalsdorf B,
    7. Obersteiner S,
    8. Gaede KI,
    9. Herzmann C,
    10. Johnson GL,
    11. Lange C,
    12. Hoenigl M
    . 2018. Evaluation of galactomannan testing, the Aspergillus-specific lateral-flow device test and levels of cytokines in bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis. Front Microbiol 9:2223. doi:10.3389/fmicb.2018.02223.
    OpenUrlCrossRef
  17. 17.↵
    1. Jenks JD,
    2. Mehta SR,
    3. Taplitz R,
    4. Law N,
    5. Reed SL,
    6. Hoenigl M
    . 2 November 2018. Bronchoalveolar lavage Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. J Infect doi:10.1016/j.jinf.2018.10.014.
    OpenUrlCrossRef
  18. 18.↵
    1. Park SY,
    2. Lee SO,
    3. Choi SH,
    4. Jeong JY,
    5. Sung H,
    6. Kim MN,
    7. Choi CM,
    8. Hong SB,
    9. Oh YM,
    10. Shim TS,
    11. Lim CM,
    12. Koh Y,
    13. Kim DS,
    14. Kim YS,
    15. Woo JH,
    16. Kim SH
    . 2011. Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis 52:e149–e152. doi:10.1093/cid/cir027.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Izumikawa K,
    2. Yamamoto Y,
    3. Mihara T,
    4. Takazono T,
    5. Morinaga Y,
    6. Kurihara S,
    7. Nakamura S,
    8. Imamura Y,
    9. Miyazaki T,
    10. Nishino T,
    11. Tsukamoto M,
    12. Kakeya H,
    13. Yanagihara K,
    14. Mine M,
    15. Yasuoka A,
    16. Tashiro T,
    17. Kohno S
    . 2012. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 50:811–817. doi:10.3109/13693786.2012.682228.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Urabe N,
    2. Sakamoto S,
    3. Sano G,
    4. Suzuki J,
    5. Hebisawa A,
    6. Nakamura Y,
    7. Koyama K,
    8. Ishii Y,
    9. Tateda K,
    10. Homma S
    . 2017. Usefulness of two Aspergillus PCR assays and Aspergillus galactomannan and beta-d-glucan testing of bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis. J Clin Microbiol 55:1738–1746. doi:10.1128/JCM.02497-16.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis
Takahiro Takazono, Yuya Ito, Masato Tashiro, Keitaro Nishimura, Tomomi Saijo, Kazuko Yamamoto, Yoshifumi Imamura, Taiga Miyazaki, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa
Journal of Clinical Microbiology Apr 2019, 57 (5) e00095-19; DOI: 10.1128/JCM.00095-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis
Takahiro Takazono, Yuya Ito, Masato Tashiro, Keitaro Nishimura, Tomomi Saijo, Kazuko Yamamoto, Yoshifumi Imamura, Taiga Miyazaki, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa
Journal of Clinical Microbiology Apr 2019, 57 (5) e00095-19; DOI: 10.1128/JCM.00095-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

β-d-glucan
AspLFD
Aspergillus
Aspergillus IgG antibody
chronic pulmonary aspergillosis
diagnosis
galactomannan
lateral flow device

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X